# A Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Systemic Lupus Erythematosus

> **NCT06373991** · PHASE1 · NOT_YET_RECRUITING · sponsor: **EdiGene Inc.** · enrollment: 12 (estimated)

## Conditions studied

- Lupus Erythematosus, Systemic

## Interventions

- **BIOLOGICAL:** ATHENA CAR-T
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT06373991
- **Lead sponsor:** EdiGene Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07-24
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-04-30
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2024-06-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06373991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06373991, "A Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06373991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*